LONDON & BOSTON & TOKYO--(BUSINESS WIRE)--Life science market intelligence company, Evaluate, Ltd., announced today that it has extended its exclusive consensus sales forecast analyses within its service platforms from 2018 to 2020. Evaluate’s consensus forecasts are derived by its expert analysts using the unweighted average of up to six of the leading equity research forecasts.
Both EvaluatePharma and EvaluateMedTech contain the new forecast information. In addition, new detail on minimum, maximum and median forecasts enables more in-depth analysis of the future direction of the pharma, biotech and medtech sectors.
An analysis using the extended consensus forecasts reveals that Sovaldi will top the list of biggest selling drugs in 2020. For further information read the full story by EP Vantage, Evaluate’s editorial team, that also reveals a surprising entrant to the elite tier of top selling drugs. “The Biggest Drugs 2020” article is available at www.evaluategroup.com/BiggestDrugs2020.
“Given its history-making launch it is no surprise that Gilead’s juggernaut Sovaldi is forecast to become the biggest drug in 2020, the big question will be how long this drug can hang onto the top spot,” said Lisa Urquhart, EP Vantage editor.
Evaluate’s premier annual report, “EvaluatePharma World Preview 2014: Outlook to 2020,” will highlight the new consensus forecast data. The report will examine the impact of patent expirations and include analysis on R&D spend as well as the leading products and companies by therapeutic area and geographies. Evaluate will release the report during the 2014 BIO Convention taking place June 23-26 in San Diego. Follow Evaluate on Twitter or LinkedIn for additional information and to access our reports.
About Evaluate, Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Evaluate supports life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Its services include EvaluatePharma, EvaluateClinicalTrials and EvaluateMedTech. A global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. Evaluate provides superior quality content, user-friendly reporting tools and outstanding customer service to solve industry problems. For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial.
About EP Vantage
Written by a team of award-winning journalists, EP Vantage provides daily financial analysis of key industry catalysts including: regulatory and patent decisions, marketing approvals, licensing deals, and M&A – giving fresh angles and insight to both current and future industry triggers. Launched in 2007 by EvaluatePharma®, EP Vantage’s unique access to EvaluatePharma and EvaluateMedTech data allows unrivalled, forward-looking coverage of the pharmaceutical, biotech and medtech industries. Visit www.epvantage.com to sign up for a free trial. On Twitter: @EPVantage.
